Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tanezumab - Eli Lilly and Company/Pfizer

Drug Profile

Tanezumab - Eli Lilly and Company/Pfizer

Alternative Names: PF-04383119; PF-4383119; RI-624; RN-624

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rinat Neuroscience
  • Developer Eli Lilly and Company; Pfizer
  • Class Monoclonal antibodies; Non-opioid analgesics
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Back pain; Musculoskeletal pain
  • Suspended Diabetic neuropathies
  • No development reported Postherpetic neuralgia
  • Discontinued Cancer pain

Most Recent Events

  • 05 Jan 2022 Adverse events data of a phase III OA SAFETY STUDY in patients with Osteoarthritis (OA) presented at ACR Convergence 2021 (ACR/ARP-2021)
  • 05 Jan 2022 Pooled adverse events data from phase III trials in Osteoarthritis presented at ACR Convergence 2021 (ACR/ARP-2021)
  • 05 Nov 2021 Pooled efficacy data from two phase III trials in Osteoarthritis presented at the ACR Convergence 2021 (ACR/ARP-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top